Edition:
United Kingdom

Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

14.55USD
14 Dec 2017
Change (% chg)

$-0.15 (-1.02%)
Prev Close
$14.70
Open
$14.75
Day's High
$14.80
Day's Low
$14.35
Volume
60,323
Avg. Vol
50,268
52-wk High
$23.00
52-wk Low
$11.80

Chart for

About

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or... (more)

Overall

Beta: --
Market Cap(Mil.): $495.06
Shares Outstanding(Mil.): 30.56
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Morgan Stanley Reports 5 Pct Passive Stake In Atara Biotherapeutics As Of Nov 27

* MORGAN STANLEY REPORTS 5.0 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS INC AS OF NOVEMBER 27 - SEC FILING Source text: (http://bit.ly/2jrEZiq) Further company coverage:

07 Dec 2017

BRIEF-Atara Biotherapeutics reports Q3 loss per share $1.02

* Atara Biotherapeutics Inc announces third quarter 2017 financial results and recent highlights

09 Nov 2017

BRIEF-Atara Biotherapeutics receives rare pediatric disease designation from FDA for Ata230

* Atara Biotherapeutics receives rare pediatric disease designation from FDA for Ata230 for treatment of congenital cytomegalovirus (CMV) infection Source text for Eikon: Further company coverage:

26 Oct 2017

BRIEF-Atara Biotherapeutics announces abstract publication for two MSParis2017 congress presentations

* Atara Biotherapeutics announces abstract publication for two MSParis2017 congress presentations, including updated interim results from a phase 1 study of autologous ATA190 in patients with progressive multiple sclerosis (MS)

16 Oct 2017

BRIEF-Atara Biotherapeutics Inc - ‍announced receipt of positive regulatory feedback from Health Canada for ATA129​

* Atara Biotherapeutics Inc - ‍announced receipt of positive regulatory feedback from Health Canada for ATA129​

11 Sep 2017

BRIEF-Atara Biotherapeutics receives FDA orphan drug designation for ATA230

* Atara Biotherapeutics receives FDA orphan drug designation for ata230

05 Sep 2017

BRIEF-Atara Biotherapeutics reports Q2 loss per share of $0.94

* Atara biotherapeutics announces second quarter 2017 financial results and recent highlights

07 Aug 2017

Earnings vs. Estimates